Home

Life-changing therapies

Innovative medicines pipeline
Macrocycle discovery platform
Collaborate with Polyphor

Latest news

See all news

Meet us at

 September 04, 2019
Publication Half Year Report 2019

Telecon 14:00h CET
 September 05, 2019
UBS | Best of Switzerland Conference

Dorint Airport-Hotel | Riethofstrasse 40 | CH-8152 Opfikon-Glattbrugg
 September 06, 2019
KOL Meeting with Dr. Peter Kaufman, Co-Chair of the Balixafortide FORTRESS Trial

Hotel The Benjamin | 125 East 50th Street | 10022 New York | 08:00h to 09:30h EDT | Webcast
 September 09, 2019
Wainwright Investors Conference

The Lotte Palace Hotel | 455 Madison Ave. | 10022 New York | USA
 September 16, 2019
KOL Meeting with Dr. Javier Cortez, Co-Chair of the Balixafortide FORTRESS Trial

Haus Zum Rueden | Limmatquai 42, Zürich | 12:15h to 13:45h CET | Webcast
 September 18, 2019
Investora | Zürich

Samsung Hall | Hoffnigstrasse 1 | CH-8600 Dübendorf | Presentation 15:25h – 16:10h

 

Event calendar

Innovative medicines pipeline

Antibiotics

Murepavadin (POL7080) – Pseudomonas infections

Phase III

OMPTA platform –  targeting Gram-negative resistant pathogens

Lead preclinical compound: POL7306

 

Preclinical

CXCR4 antagonist

Balixafortide (POL6326) – for novel immune-oncology agent for combination therapy

Fast Track Designation granted by FDA

Phase III

Inhaled elastase inhibitor

POL6014 – Cystic Fibrosis

Outlicensed to Santhera Pharmaceuticals 14.02.2018

Phase I

Macrocycle discovery platform

New modalities to address challenging biological targets

Learn more